Medical cannabis connected packaging — common questions

Can you advertise medical cannabis to the public through a QR portal?+

No. Cannabis-based products for medicinal use (CBPMs) are prescription-only medicines under the UK's specials route, and advertising POMs to the general public is prohibited by regulation 279 of the Human Medicines Regulations 2012 and the MHRA Blue Guide. The equivalent EU rule is Article 88 of Directive 2001/83/EC. SmartLinks builds the portal as patient-only content — PIL, batch, dosing, safety, refill — never as consumer marketing.

Why is there no loyalty, discount or cross-sell layer?+

Consumer-style engagement — points, referral bounties, discount codes, cross-sell — is inappropriate for a scheduled POM and can be treated as unlawful promotion or inducement. The medical cannabis flow deliberately replaces those mechanics with clinic-mediated refill, adherence diary and prescriber-authored education. The CBD page is where consumer mechanics live for the non-POM cannabinoid range.

Is a digital PIL actually allowed?+

Yes. The MHRA best-practice guidance on patient information leaflets supports digital PIL alongside paper, and the EMA electronic product information (ePI) framework is heading the same way for centrally-authorised products. SmartLinks routes the digital PIL for the exact batch and product a patient scans.

How is adverse-event reporting handled?+

The portal offers a one-tap route to the MHRA Yellow Card scheme, prefilled with the product name, batch and serial from the scan — reducing friction for patients and prescribers reporting suspected adverse reactions.

How does refill work without a consumer checkout?+

Refill requests are routed to the patient's prescribing clinic (not a shop cart), with prescription and identity verification before any dispensing conversation. The pack triggers the request; the clinic remains the authoriser — keeping the flow inside the specials-route and prescriber-of-record framework.